Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 49, 2013, Pages 19902-19907

  De Titta, Alexandre ^a   Ballester, Marie ^a   Julier, Ziad ^a   Nembrini, Chiara ^a   Jeanbart, Laura ^a   Van Der Vlies, André J ^a   Swartz, Melody A ^a,b   Hubbell, Jeffrey A ^a,b  

^a Chemical Engineering and Biochemistry Section   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; NANOCARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DENDRITIC CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INJECTIONS, INTRADERMAL; LYMPH NODES; MICE; NANOPARTICLES; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; VACCINES, SUBUNIT;

EID: 84889650175     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1313152110     Document Type: Article

References (42)

1. Swartz MA, Hirosue S, Hubbell JA (2012) Engineering approaches to immunotherapy. Sci Transl Med 4(148):rv9.
2. Moon JJ, Huang B, Irvine DJ (2012) Engineering nano- and microparticles to tune immunity. Adv Mater 24(28):3724-3746.
3. Li WA, Mooney DJ (2013) Materials based tumor immunotherapy vaccines. Curr Opin Immunol 25(2):238-245.
4. Bourquin C, et al. (2008) Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 181(5):2990-2998.
5. Beaudette TT, et al. (2009) In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm 6(4): 1160-1169.
6. Li AV, et al. (2013) Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med 5(204):ra130.
7. Hafner AM, Corthésy B, Merkle HP (2013) Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev 65(10):1386-1399.
8. Leleux J, Roy K (2013) Micro and nanoparticle-based delivery systems for vaccine immunotherapy: An immunological and materials perspective. Adv Healthc Mater 2(1):72-94.
9. Rozenfeld JHK, Silva SR, Ranéia PA, Faquim-Mauro E, Carmona-Ribeiro AM (2012) Stable assemblies of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo. J Control Release 160(2):367-373.
10. Alving CR, Rao M (2008) Lipid A and liposomes containing lipid A as antigens and adjuvants. Vaccine 26(24):3036-3045.
11. Andrews CD, Provoda CJ, Ott G, Lee K-D (2011) Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation. Bioconjug Chem 22(7):1279-1286.
12. Storni T, et al. (2004) Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172(3):1777-1785.
13. Ballester M, et al. (2011) Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 29(40): 6959-6966.
14. Nembrini C, et al. (2011) Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci USA 108(44):E989-E997.
15. Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA, Swartz MA (2010) Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 28(50):7897-7906.
16. van der Vlies AJ, O'Neil CP, Hasegawa U, Hammond N, Hubbell JA (2010) Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. Bioconjug Chem 21(4):653-662.
17. Kourtis IC, et al. (2013) Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE 8(4):e61646.
18. Foster S, Duvall CL, Crownover EF, Hoffman AS, Stayton PS (2010) Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug Chem 21(12):2205-2212.
19. Krieg AM (2012) CpG still rocks! Update on an accidental drug. Nucleic Acid Ther 22(2):77-89.
20. Marschner A, et al. (2005) CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur J Immunol 35(8):2347-2357.
21. Huber JP, Farrar JD (2011) Regulation of effector and memory T-cell functions by type I interferon. Immunology 132(4):466-474.
22. Krug A, et al. (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31(7): 2154-2163.
23. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760.
24. Vollmer J, et al. (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34(1):251-262.
25. Gonzalez SF, et al. (2011) Trafficking of B cell antigen in lymph nodes. Annu Rev Immunol 29:215-233.
26. Reddy ST, et al. (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 25(10):1159-1164.
27. Kerkmann M, et al. (2005) Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem 280(9):8086-8093.
28. Pulendran B, Tang H, Denning TL (2008) Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr Opin Immunol 20(1):61-67.
29. Agnellini P, et al. (2008) Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol 180(3):1517-1525.
30. Sad S, Krishnan L (2003) Maintenance and attrition of T-cell memory. Crit Rev Immunol 23(1-2):129-147.
31. Schwarz K, et al. (2003) Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 33(6):1465-1470.
32. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239(1):178-196.
33. Kandimalla ER, et al. (2002) Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem 13(5):966-974.
34. Putta MR, et al. (2010) Peptide conjugation at the 5′-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity. Bioconjug Chem 21(1):39-45.
35. Purswani MU, Eckert SJ, Arora HK, Noel GJ (2002) Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J Antimicrob Chemother 50(1):51-58.
36. Breckpot K, et al. (2003) Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 5(8):654-667.
37. Vasconcelos JR, et al. (2012) Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol 3:358.
38. Rothenfusser S, et al. (2004) CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 103(6):2162-2169.
39. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 8(4):247-258.
40. Brincks EL, Katewa A, Kucaba TA, Griffith TS, Legge KL (2008) CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol 181(7):4918-4925.
41. Zhang Y, et al. (2007) Th1 cell adjuvant therapy combined with tumor vaccination: A novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol 19(2):151-161.
42. Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW (2004) The rate of the CD8- dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 173(3):1738-1743.